Parkin/PARK2 Polyclonal Antibody | Bioss bs-1865R product information

This webpage contains legacy information. The product is either no longer available from the supplier or has been delisted at Labome.

product summary

company name :

Bioss

product type :

antibody

product name :

Parkin/PARK2 Polyclonal Antibody

catalog :

bs-1865R

quantity :

100 ul

clonality :

polyclonal

host :

domestic rabbit

conjugate :

nonconjugated

reactivity :

human, mouse, rat

application :

western blot, immunocytochemistry, immunohistochemistry - paraffin section

product information

sku :

bs-1865R

name :

Parkin/PARK2 Polyclonal Antibody

category :

Primary Antibody

conjugation :

Unconjugated

host :

Rabbit

target protein :

PARK2

modification :

Unmodified

clonality :

Polyclonal

isotype :

IgG

concentration :

1ug/ul

public immunogen range :

390-440/465

subcellular locations :

Cytoplasm, Nucleus

source :

KLH conjugated synthetic peptide derived from human E3 ubiquitin-protein ligase parkin

gene id link :

Entrez Gene: 5071

swiss prot :

O60260

swiss prot link :

Swiss Prot: O60260

applications :

WB, IHC-P, IF(IHC-P)

applications with dilutions :

WB(1:100-1000), IHC-P(1:100-500), IF(IHC-P)(1:50-200)

cross reactive species :

Human, Mouse, Rat

size :

100 ul

background :

Functions within a multiprotein E3 ubiquitin ligase complex, catalyzing the covalent attachment of ubiquitin moieties onto substrate proteins, such as BCL2, SYT11, CCNE1, GPR37, RHOT1/MIRO1, MFN1, MFN2, STUB1, a 22 kDa O-linked glycosylated isoform of SNCAIP, SEPT5, TOMM2, USP3, ZNF746 and AIMP2. Mediates monoubiquitination as well as 'Lys-48'-linked and 'Lys-63'-linked polyubiquitination of substrates depending on the context. Participates in the removal and/or detoxification of abnormally folded or damaged protein by mediating 'Lys-63'-linked polyubiquitination of misfolded proteins such as PARK7: 'Lys-63'-linked polyubiquitinated misfolded proteins are then recognized by HDAC6, leading to their recruitment to aggresomes, followed by degradation. Mediates 'Lys-63'-linked polyubiquitination of SNCAIP, possibly playing a role in Lewy-body formation. Mediates monoubiquitination of BCL2, thereby acting as a positive regulator of autophagy. Promotes the autophagic degradation of dysfunctional depolarized mitochondria (mitophagy) by the ubiquitination of mitochondrial proteins such as TOMM2, RHOT1/MIRO1 and USP3 (PubMed:24896179). Mediates 'Lys-48'-linked polyubiquitination of ZNF746, followed by degradation of ZNF746 by the proteasome; possibly playing a role in the regulation of neuron death. Limits the production of reactive oxygen species (ROS). Regulates cyclin-E during neuronal apoptosis. In collaboration with CHPF isoform 2, may enhance cell viability and protect cells from oxidative stress. Independently of its ubiquitin ligase activity, protects from apoptosis by the transcriptional repression of p53/TP53. May protect neurons against alpha synuclein toxicity, proteasomal dysfunction, GPR37 accumulation, and kainate-induced excitotoxicity. May play a role in controlling neurotransmitter trafficking at the presynaptic terminal and in calcium-dependent exocytosis. May represent a tumor suppressor gene.

purification :

Purified by Protein A.

storage :

Aqueous buffered solution containing 1% BSA, 50% glycerol and 0.09% sodium azide. Store at -20°C for 12 months.

synonyms :

PDJ; PRKN; AR-JP; LPRS2; E3 ubiquitin-protein ligase parkin; Parkinson juvenile disease protein 2; Parkinson disease protein 2; PARK2

lead time :

3 to 5 business days.